Skip to the main content

Creative Touch Permanent Makeup and Aesthetics

Poly-L-Lactic Acid

MedicalTherapy Treatment

Poly-L-lactic acid (PLLA) is a biodegradable biostimulator whose mechanism is categorically distinct from -based fillers. Rather than replacing lost volume directly, its microspheres initiate a controlled foreign body response that recruits and reprogrammes macrophages toward a repair-oriented state, driving activation and new Type I and III collagen deposition over months. A second, independent route directly activates fibroblast PI3K/AKT signalling, suppressing senescence markers and restoring proliferative capacity in aged fibroblasts. Results develop gradually across three sessions, with full benefit extending well beyond the point at which PLLA itself has been metabolised – giving it a 24-to-36-month durability that reflects genuine collagen architecture rather than the presence of an implanted material. [8]

Poly-L-lactic acid (PLLA) is a synthetic, biodegradable polymer in the alpha-hydroxy acid family, injected as microspheres into the deep or to stimulate the ’s own collagen-producing machinery rather than replace lost volume with an external material. Its mechanism is fundamentally different from hyaluronic acid fillers: there is no structural volume effect once the solvent carrier is absorbed within the first week, and all visible improvement that follows reflects new collagen architecture laid down by the client’s own fibroblasts. This distinction makes PLLA one of the most durably effective treatments available for structural collagen decline, and also the one that requires the most careful expectation-setting about its timeline. [1]

How PLLA Works

PLLA stimulates collagen through two independent mechanisms operating on different timescales, which is why its clinical results are both slower to appear and more sustained than treatments relying on a single signalling route.

The foreign body response route begins within the first month post-injection. PLLA microspheres are recognised as a foreign material and encapsulated by macrophages and lymphocytes. Critically, this is not a harmful inflammatory reaction – the microspheres are designed to guide macrophage polarisation toward an M2 repair-oriented state rather than a pro-inflammatory M1 state. M2 macrophages secrete and IL-10, which activate adjacent fibroblasts via TGF-β/SMAD2/3 signalling, upregulating COL1A1, COL3A1, TIMP-1, and TIMP-2 gene expression. The TIMP upregulation simultaneously slows MMP-mediated collagen degradation, meaning PLLA addresses both sides of the net collagen balance – synthesis up, degradation reduced. [8][13]

The direct fibroblast route operates independently of the macrophage cascade. PLLA activates fibroblast PI3K/AKT signalling directly, driving collagen I and III synthesis and production through a pathway that also suppresses the senescence markers SA-β-gal, p16, and p21 via inhibition of the p53/p21 axis. [8] The significance of this becomes clear when the normal age-related decline of this pathway is understood: IGF-1 signalling, which activates PI3K/AKT to support fibroblast survival and collagen production, declines progressively with age. As signalling reduces, fibroblasts lose both their proliferative capacity and their ability to maintain dermal architecture independently of any direct TGF-β signalling impairment. [11] PLLA’s direct PI3K/AKT activation restores this specific pathway.

PLLA and the Senescent Fibroblast

Fibroblast senescence is one of the most consequential and least discussed drivers of structural . – those that have entered an irreversible growth arrest via p16INK4a/RB or p53/p21 pathways – do not simply produce less collagen. They actively drive further deterioration through what is termed the (SASP): a chronic low-grade inflammatory output of , IL-1β, , and elevated MMPs that compounds collagen degradation and promotes senescence in surrounding cells through paracrine signalling. [7] Research has quantified the structural consequence: senescence-associated changes produce a 68% reduction in Type I procollagen content and a 30% decrease in fibroblast collagen-synthetic capacity, independent of chronological collagen loss measured by other mechanisms. [7]

The macrophage environment compounds this further in aged skin. The ratio of pro-inflammatory M1 macrophages to repair-oriented M2 macrophages increases with age, and conditioned media from M1 macrophages measurably increases the number of SA-β-gal-positive (senescent) dermal fibroblasts. Conversely, conditioned media from M2 macrophages actively inhibits fibroblast senescence. [8] In aged skin, the tissue is therefore not only producing fewer repair signals, it is generating a pro-senescent macrophage environment that is actively maintaining the fibroblast senescence it has created.

PLLA interrupts this cycle at two points simultaneously. Its M2 polarisation shifts the macrophage environment away from the pro-senescent M1 state, removing one of the signals driving ongoing fibroblast senescence. Its direct PI3K/AKT activation then works on fibroblasts themselves, suppressing the p53/p21 axis and the SA-β-gal senescence marker, partially restoring the proliferative and collagen-producing capacity that senescence has reduced. This dual-point intervention is mechanistically distinct from treatments that provide a synthesis signal without addressing the senescence environment those signals are working into.

The PLLA Timeline

Understanding PLLA’s degradation and collagen accumulation timeline is essential for both treatment planning and client communication.

TimepointWhat is happening in the tissue
Day 1–7Solvent carrier absorbed; any immediate soft tissue effect disappears
Week 1–4PLLA microspheres colonise in situ; macrophage encapsulation begins
Month 1–3TGF-β secretion drives fibroblast activation; new collagen begins forming; Type I collagen measurably increased
Month 3–6PLLA microspheres begin hydrolysing to lactic acid; collagen deposition continues accumulating
Month 6–9Particles largely degraded; lactic acid metabolised to CO₂ and water via Krebs cycle
Month 9–24+PLLA fully metabolised; regenerated fibroblasts continue collagen production independently

The durability of PLLA results – 24 to 36 months clinically, with some studies reporting effects beyond that – therefore does not reflect the continued presence of the implanted material. The PLLA has gone; what remains is a restored fibroblast population producing collagen from its own recovered capacity. [1] [9]

Evidence Base

The clinical evidence for PLLA is well-established across both volumetric and collagen endpoints. A 2025 multicenter RCT of 331 subjects found PLLA achieved 90.57% improvement in midfacial volume at 12 months, outperforming HA filler in that comparison. [12] A separate 260-participant RCT demonstrated 67.6% improvement in wrinkle severity at 52 weeks alongside greater than 90% patient satisfaction. [12] Histological biopsy studies confirm new Type I and III collagen deposition around PLLA particles from approximately six months, with collagen architecture persisting well beyond particle degradation. [1]

At the molecular level, collagen Type I expression measured 65.5% above baseline at three months post-injection in tissue studies, with a modest reduction at six months as the acute macrophage response settles, followed by stabilisation of the restored collagen architecture. [3]

Safety Profile and Technique Considerations

PLLA’s safety record across large treatment cohorts is favourable when injection technique and reconstitution protocols are followed correctly. In a 274-treatment retrospective study using immediate reconstitution, the most common adverse events were bruising (6.57% of facial treatments) and mild pain (3.07%), both resolving within the first week without intervention. One subcutaneous nodule was reported, resolving within two weeks after saline injection. [10]

The most clinically significant risk is delayed nodule formation, historically reported across PLLA literature at an incidence ranging from 1% to 44% – a wide range that reflects technique variation rather than inherent material risk. [5] The primary risk factors are inadequate product reconstitution, insufficient dilution, superficial injection depth, and failure to perform the recommended post-treatment massage protocol. With appropriate dilution (9mL per vial for facial use), blunt cannula technique, and consistent massage, nodule rates in contemporary practice are substantially lower than historical reports suggest.

PLLA should not be injected into the periorbital area or . These anatomically thin and mechanically dynamic zones present an unfavourable environment for the foreign body response PLLA depends on, and adverse event rates in these regions are disproportionately higher. [2]

Realistic Expectations

PLLA is not a treatment for clients seeking immediate visible change. The honest expectation is that results emerge gradually over six to eight weeks after each session, continue developing for months after the final session, and represent a genuine structural improvement in dermal collagen architecture rather than soft tissue augmentation. For clients who understand and accept this timeline, the durability PLLA offers – and particularly its capacity to partially restore senescent fibroblast function – makes it one of the most mechanistically comprehensive options available for significant, long-standing structural collagen decline.

Published

Clinical Application

PLLA sits in a distinct position at Creative Touch: it is the treatment we reach for when a client is thinking about the longer view – where the conversation is about restoring what has been gradually lost over years rather than addressing a recent change, and where the client is willing to invest in a slower build in exchange for a more structurally durable outcome.

The clients who benefit most from PLLA are those where structural collagen decline is the primary story. Not reactive skin, not active barrier disruption – those presentations call for different first steps. PLLA is most appropriate when the dermis has simply been losing ground over time: post-menopausal skin where fibroblast senescence has reduced the tissue’s capacity to maintain its own collagen architecture, photoaged skin where years of -driven degradation have outpaced synthesis, or clients in their mid-forties onwards who are noticing a slow but progressive loss of structural quality that topical actives can support but not fundamentally reverse.

Why PLLA Works Differently in Post-Menopausal Skin

The perimenopausal and post-menopausal context is where PLLA’s fibroblast senescence mechanism matters most. Most collagen-stimulating treatments work by providing the signals that tell fibroblasts to produce more – TGF-β via iPRF, mechanical tension via HA , macrophage-mediated TGF-β via . All of these approaches are asking fibroblasts to perform. Where senescence is part of the picture, that performance capacity is reduced: the cells are present, but their responsiveness to stimulation signals, their proliferative activity, and their collagen output have all declined independently of what those signals are doing.

PLLA’s direct activation of the PI3K/AKT pathway in fibroblasts addresses this at a more fundamental level: it suppresses the p53/p21 senescence axis, measurably reducing SA-β-gal and related markers of cellular ageing. [8] The treatment is not simply asking a senescent cell to do more, it is partially restoring that cell’s capacity to function. For clients where other collagen stimulators have produced underwhelming results, this mechanism deserves consideration as the reason why.

Choosing Between PLLA, iPRF, and Polynucleotides for the Perimenopausal or Photoaged Presentation

These three treatments all address collagen decline in ageing skin, but through different mechanisms that make them suited to different stages and dominant drivers of that decline. Understanding where each treatment is most effective, and where each has limitations, is what allows us to match the right approach to each client rather than defaulting to a single protocol.

iPRFPolynucleotidesPLLA
Primary collagen signalDirect TGF-β/SMAD via platelet growth factorsIndirect: M2 macrophage → TGF-β/IL-10 → SMAD2/STAT3 in fibroblastsIndirect: M2 macrophage → TGF-β/SMAD2/3 + direct PI3K/AKT
Works in senescent fibroblast environment?Limited – senescent cells show reduced direct TGF-β responsivenessYes – SMAD2 and STAT3 phosphorylation confirmed in senescent fibroblasts via macrophage routeYes – directly suppresses p53/p21 senescence axis; restores PI3K/AKT capacity
Addresses fibroblast senescence markers?NoPartially – reduces SASP-driving oxidative stress via CREB/PCK1 axisYes – directly reduces SA-β-gal, p16, p21
MMP suppressionYes – MMP-1 via ROS reductionYes – NF-κB inhibition → MMP-1/3/9Yes – TIMP-1/2 upregulation
Macrophage environmentProvides growth factors; does not directly reprogramme macrophagesM2 polarisation via A2AR/CREB/PCK1M2 polarisation via foreign body response
Onset of visible results2–4 weeks4–8 weeks6–8 weeks minimum
Durability3–6 months6–12 months24–36 months
Best suited forActive UV damage; early-to-moderate collagen decline; fibroblasts still TGF-β responsiveInflammatory or perimenopausal environment; moderate collagen decline with SASP componentSignificant structural decline; post-menopausal; fibroblast senescence prominent; long-horizon investment

The practical implication for treatment planning: performs most effectively in skin where fibroblasts retain functional TGF-β responsiveness – earlier presentations, less senescent fibroblast populations, active UV damage rather than long-standing structural loss. [6] Polynucleotides reach into senescent fibroblast populations through their macrophage route and are effective at quietening the SASP-driven inflammatory environment that compounds collagen loss, making them particularly valuable as a preparation step and for ongoing maintenance. [4] PLLA addresses fibroblast senescence most directly and durably, but requires the longest commitment and is most appropriate where the pattern of decline suggests senescence rather than simple stimulus deficiency is the limiting factor. [8]

In practice, these three treatments are more often complementary than competing. Polynucleotides quieten the environment; iPRF provides the collagen stimulus in the near term; PLLA rebuilds fibroblast capacity for the longer term. For clients where all three presentations are active – photoaged skin with some inflammatory burden, perimenopausal hormonal context, and evidence of structural collagen decline – sequencing across all three over time is a more complete approach than any single modality.

Setting Expectations: The PLLA Conversation

Because the initial filling effect of the solvent carrier disappears within the first week, PLLA requires more careful expectation-setting than almost any other treatment in our portfolio. Clients who are not prepared for the temporary disappearance of that early result can interpret it as the treatment not working and may present for assessment at exactly the point when the tissue is simply in the early stages of the macrophage cascade that precedes visible improvement.

We typically frame PLLA as a three-session investment with a six-to-twelve month development window. Sessions are spaced four to six weeks apart; the first visible improvement usually begins at six to eight weeks from the first session. The full result continues developing after the final session and in many cases looks better at twelve months than at six. Clients who understand this – and who have chosen PLLA precisely because they want something that will still be working in two to three years – tend to be among the most satisfied in our practice.

Treatment Sequencing with PLLA

PLLA works best in a quieter tissue environment. Introducing it alongside or immediately after treatments that create significant acute inflammation – ablative laser, aggressive – risks disrupting the controlled foreign body response that the mechanism depends on. In practice we plan PLLA sessions as a distinct treatment course rather than layering them within a dense multi-modality protocol.

Where a client also has active inflammatory burden – reactive skin, significant sebaceous congestion, perimenopausal skin sensitivity – we address that first. Polynucleotides are a particularly logical precursor: they quieten MMP activity and the inflammatory environment, creating a tissue context in which PLLA’s macrophage-mediated cascade can proceed more cleanly. [4] Where HA skin boosters are also appropriate – as they often are in clients with both ground substance depletion and structural collagen decline – these can be scheduled between PLLA sessions without interference, addressing the hydration and mechanical tension layer whilst the PLLA cascade is building.

Where We Don’t Use PLLA

The periorbital area and lips are outside the appropriate treatment zone for PLLA. The anatomy is too thin, the movement too constant, and the adverse event profile in these regions is disproportionate to the risk. For periorbital volume loss, HA preparations specifically formulated for that zone, or the indirect collagen and ground substance support of polynucleotides and iPRF, are the appropriate choices. [2]

References

  1. Ao YJ, Yi Y, Wu GH (2024). Application of PLLA (Poly-L-Lactic acid) for rejuvenation and reproduction of facial cutaneous tissue in aesthetics: A review. Medicine (Baltimore), 103(11), e37506 .

  2. Avelar L, Ong A, Ong D, et al. (2023). Consensus recommendations on the use of injectable poly-l-lactic acid in Asian patients. J Cosmet Dermatol, 22(12), 3223-3231 .

  3. Avelar LE, Nabhani S, Wüst S (2025). Unveiling the Mechanism: Injectable Poly-L-Lactic Acid’s Evolving Role-Insights From Recent Studies. J Cosmet Dermatol, 24(1), e16635 .

  4. Byun KA, Park HJ, Oh S, et al. (2025). Polynucleotides Enhance Collagen Synthesis via Modulating Phosphoenolpyruvate Carboxykinase 1 in Senescent Macrophages: Experimental Evidence. Int J Mol Sci, 26(17) .

  5. Cao Q, Chen J, Zhang Z, et al. (2025). Faster efficacy and reduced nodule occurrence with PLLA (poly-l-lactic acid) porous microspheres. Front Bioeng Biotechnol, 13, 1571820 .

  6. Li Y, Song P, He J, et al. (2022). Comparison Between Injectable Platelet-rich Fibrin and Platelet-rich Plasma in Ameliorating UVA-induced Photoaging in Human Dermal Fibroblasts via the Activation of TGF-β/Smad Signaling Pathway. Photochem Photobiol, 98(6), 1395-1401 .

  7. Nan L, Guo P, Hui W, et al. (2025). Recent advances in dermal fibroblast senescence and skin aging: unraveling mechanisms and pioneering therapeutic strategies. Front Pharmacol, 16, 1592596 .

  8. Oh S, Lee JH, Kim HM, et al. (2023). Poly-L-Lactic Acid Fillers Improved Dermal Collagen Synthesis by Modulating M2 Macrophage Polarization in Aged Animal Skin. Cells, 12(9) .

  9. Ray S, Ta HT (2020). Investigating the Effect of Biomaterials Such as Poly-(l-Lactic Acid) Particles on Collagen Synthesis In Vitro: Method Is Matter. J Funct Biomater, 11(3) .

  10. Vasconcelos-Berg R, Real J, Wenz F, et al. (2024). Safety of the Immediate Reconstitution of Poly-l-Lactic Acid for Facial and Body Treatment-A Multicenter Retrospective Study. J Cosmet Dermatol, 23(12), 3918-3923 .

  11. Zhang J, Yu H, Man MQ, et al. (2024). Aging in the dermis: Fibroblast senescence and its significance. Aging Cell, 23(2), e14054 .

  12. Zhang Y, Zhang X, Gao X, et al. (2025). Efficacy and Safety of Poly-l-Lactic Acid for Correction of Midfacial Volume Loss and Contour Defects: A Prospective, Multicenter, Randomized, Parallel-Controlled, Evaluator-Blinded, Superiority Trial. J Cosmet Dermatol, 24(7), e70230 .

  13. Zhu W, Dong C (2023). Poly-L-Lactic acid increases collagen gene expression and synthesis in cultured dermal fibroblast (Hs68) through the TGF-β/Smad pathway. J Cosmet Dermatol, 22(4), 1213-1219 .

Also Known As

  • PLLA
  • Sculptra

Therapeutic Relationships

Therapeutic Context

  • Stimulates
  • Stimulates

Indications & References

  • this Related anatomy
  • this Related anatomy

Learn More

This topic is discussed in 1 article: